{"altmetric_id":21444191,"counts":{"readers":{"mendeley":1,"citeulike":1,"connotea":0},"total":{"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4ed3cf058f610002b83","authors":["A Astrup","R Carraro","N Finer","A Harper","M Kunesova","M E J Lean","L Niskanen","M F Rasmussen","A Rissanen","S R\u00f6ssner","M J Savolainen","L Van Gaal"],"doi":"10.1038\/ijo.2011.203","endpage":"890","first_seen_on":"2017-06-30T17:11:40+00:00","issns":["0307-0565","1476-5497"],"issue":"6","journal":"International Journal of Obesity","last_mentioned_on":1496275200,"links":["http:\/\/www.nature.com\/ijo\/journal\/v36\/n6\/full\/ijo2011203a.html"],"pmid":"22689098","pubdate":"2012-06-01T00:00:00+00:00","publisher":"Nature Publishing Group","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"},{"name":"Education","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences","Nursing"],"startpage":"890","subjects":["metabolism"],"title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide","type":"article","volume":"36","mendeley_url":"http:\/\/www.mendeley.com\/research\/erratum-safety-tolerability-sustained-weight-loss-2-years-oncedaily-human-glp1-analogue-liraglutide"},"altmetric_score":{"score":3,"score_history":{"1y":3,"6m":3,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":8296164,"mean":6.9911317525872,"rank":2119120,"this_scored_higher_than_pct":60,"this_scored_higher_than":5045796,"rank_type":"exact","sample_size":8296164,"percentile":60},"similar_age_3m":{"total_number_of_other_articles":224245,"mean":12.011985123348,"rank":73200,"this_scored_higher_than_pct":66,"this_scored_higher_than":148982,"rank_type":"exact","sample_size":224245,"percentile":66},"this_journal":{"total_number_of_other_articles":2458,"mean":16.09493040293,"rank":1394,"this_scored_higher_than_pct":31,"this_scored_higher_than":780,"rank_type":"exact","sample_size":2458,"percentile":31},"similar_age_this_journal_3m":{"total_number_of_other_articles":44,"mean":15.879906976744,"rank":24,"this_scored_higher_than_pct":45,"this_scored_higher_than":20,"rank_type":"exact","sample_size":44,"percentile":45}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor":1},"by_discipline":{"Unspecified":1}}}},"posts":{"policy":[{"title":"Obese, overweight with risk factors: liraglutide (Saxenda)","url":"https:\/\/www.nice.org.uk\/guidance\/es14\/resources\/obese-overweight-with-risk-factors-liraglutide-saxenda-pdf-1158115342021","license":"public","citation_ids":[4237112,4237112,4409001,16663454,6333485,257243,21444191,495851,4685455,4685455,21444196,21444198],"posted_on":"2017-06-01T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/advice\/es14\/chapter\/Key-points","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-0cb25a7d58fff01060c350acb1895a2233da747f0f201bca05b8bcbda3f02677.jpg"}}]}}